

Jashin J Wu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3219919/jashin-j-wu-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

321
papers

6,216
citations

40
h-index

70
g-index

342
ext. papers

7,772
ext. citations

4.3
avg, IF

6.13
L-index

#	Paper	IF	Citations
321	Psoriasis Biologic Agents in Special Populations. <i>Updates in Clinical Dermatology</i> , 2022 , 111-124	0.2	
320	Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2021 , 32, 693-700	2.8	3
319	Risk of atypical mycobacterial infections in psoriasis patients during IL-17 inhibitor therapy. <i>Journal of Dermatological Treatment</i> , 2021 , 32, 495-496	2.8	
318	Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites. <i>Journal of Dermatological Treatment</i> , 2021 , 32, 916-921	2.8	1
317	The risk of COVID-19 infection in patients with atopic dermatitis: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	3
316	Biologics update: IL-17 inhibitors. <i>Dermatological Reviews</i> , 2021 , 2, 269	0.2	
315	Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2021 , 11, 2147-2157	4	0
314	Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE). <i>Journal of Dermatological Treatment</i> , 2021 , 32, 883-893	2.8	3
313	Review of treatments for generalized pustular psoriasis. <i>Journal of Dermatological Treatment</i> , 2021 , 32, 492-494	2.8	5
312	An evaluation of shade-seeking and long-sleeved shirt use in Asian Americans. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	1
311	Asian Americans are less likely to wear sunscreen compared with non-Hispanic whites. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	4
310	Characterization of non-responders to interleukin-17 inhibitors in moderate to severe psoriasis patients enrolled in the Corrona Psoriasis Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e531-e533	4.6	
309	Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review. <i>American Journal of Clinical Dermatology</i> , 2021 , 22, 425-442	7.1	13
308	Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive review. <i>Dermatologic Therapy</i> , 2021 , 34, e14974	2.2	
307	Preliminary outcomes of 2020-2021 dermatology residency application cycle and adverse effects of COVID-19. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, e263-e264	4.5	1
306	Use of systemic therapies for psoriasis in the COVID-19 era. <i>Journal of Dermatological Treatment</i> , 2021 , 1-4	2.8	7
305	Improvement in body surface area is associated with better quality of life among patients with psoriasis in the Corrona Psoriasis Registry. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1715-1717	4.5	

304	Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 432-470	4.5	46
303	Interleukin 23 Inhibitors 2021 , 321-329.e2		
302	Reply to Letter to the Editor Regarding: "Applying to dermatology residency during the COVID-19 pandemic". <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, e31-e32	4.5	
301	Two-Year US Pharmacovigilance Report on Brodalumab. <i>Dermatology and Therapy</i> , 2021 , 11, 173-180	4	6
300	Prevalence of psoriasis among adults in the US 2009-2010 and 2013-2014 National Health and Nutrition Examination Surveys. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 767-769	4.5	9
299	A response to "Male balding is a major risk factor for severe COVID-19". <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, e87-e88	4.5	2
298	Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. <i>Journal of Dermatological Treatment</i> , 2021 , 32, 484-491	2.8	1
297	A systematic review of treatment strategies for erythrodermic psoriasis. <i>Journal of Dermatological Treatment</i> , 2021 , 32, 49-55	2.8	9
296	Abrocitinib for atopic dermatitis. <i>Lancet, The</i> , 2021 , 397, 195-196	4.0	0
295	Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris. <i>Journal of Dermatological Treatment</i> , 2021 , 1-3	2.8	1
294	Association between atopic dermatitis and osteoarthritis among US adults in the 1999-2006 NHANES. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e375-e377	4.6	0
293	Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry. <i>Journal of Comparative Effectiveness Research</i> , 2021 , 10, 157-167	2.1	0
292	Association between psoriasis and thyroid dysfunction among US adults in the 2009-2014 National Health and Nutrition Examination Survey. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	2
291	Characteristics of hospitalizations and emergency department visits due to generalized pustular psoriasis in the United States. <i>Current Medical Research and Opinion</i> , 2021 , 37, 1697-1703	2.5	2
290	The Use of Real-World Data to Evaluate the Association Between Atopic Dermatitis and Cardiovascular Disease: A Retrospective Claims Analysis. <i>Dermatology and Therapy</i> , 2021 , 11, 1707-1715 ⁴		1
289	Reply to "Correspondence to Association between psoriasis and asthma among United States adults in the 2009-2014 National Health and Nutrition Examination Survey". <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	
288	Bimekizumab versus Adalimumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021 , 385, 1149-1150	3.5	0
287	Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial. <i>Dermatology and Therapy</i> , 2021 , 11, 327-330	4	1

286	Comparison of Guidelines for the Use of Interleukin-17 Inhibitors for Psoriasis in the United States, Britain, and Europe: A Critical Appraisal and Comprehensive Review. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2021 , 14, 55-59	1.2	
285	Phototherapy trends in dermatology 2015-2018.. <i>Journal of Dermatological Treatment</i> , 2021 , 1-2	2.8	
284	Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review. <i>Journal of Dermatological Treatment</i> , 2020 , 1-6	2.8	1
283	Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, e251-e252	4.5	13
282	Clinical management of psoriasis patients during the COVID-19 pandemic. <i>Journal of Dermatological Treatment</i> , 2020 , 1-2	2.8	7
281	Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2020 , 1-11	2.8	9
280	Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 459-466	4.1	3
279	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1445-1486	4.5	79
278	Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 483-491	7.1	9
277	Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. <i>Journal of Medical Economics</i> , 2020 , 23, 641-649	2.4	2
276	Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1449-1456	4.6	19
275	Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2020 , 156, 649-658	5.1	62
274	Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence. <i>Dermatology and Therapy</i> , 2020 , 10, 351-364	4	13
273	Efficacious psoriasis treatment improves patients' work productivity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e593-e596	4.6	1
272	The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2020 , 13, 44-48	1.2	9
271	Psoriasis and Co-morbidity. <i>Acta Dermato-Venereologica</i> , 2020 , 100, adv00033	2.2	17
270	Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 351-360	1.5	24
269	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 161-201	4.5	63

268	Applying to dermatology residency during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1214-1215	4.5	3
267	Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review. <i>Journal of Dermatological Treatment</i> , 2020 , 1-5	2.8	2
266	Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics. <i>Journal of Comparative Effectiveness Research</i> , 2020 , 9, 767-779	2.1	3
265	Ruxolitinib cream for the treatment of vitiligo. <i>Lancet, The</i> , 2020 , 396, 1735-1736	4.0	3
264	Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, e433-e434	4.5	1
263	The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. <i>Advances in Therapy</i> , 2020 , 37, 4491-4518	4.1	12
262	A cross-sectional study of YouTube videos as a source of patient information about phototherapy and excimer laser for psoriasis. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 707-710	2.8	9
261	Psoriasis-associated itch: etiology, assessment, impact, and management. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 18-26	2.8	4
260	Treatments for inverse psoriasis: a systematic review. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 786-793	2.8	9
259	Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 342-343	2.8	4
258	A cross-sectional study of YouTube videos as a source of patient information about topical psoriasis therapies. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 366-369	2.8	10
257	Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 359-365	2.8	11
256	Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis. <i>Current Medical Research and Opinion</i> , 2020 , 36, 169-176	2.5	6
255	Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials. <i>British Journal of Dermatology</i> , 2020 , 182, 880-888	4	8
254	Dupilumab for atopic dermatitis: what are patients learning on YouTube?. <i>Journal of Dermatological Treatment</i> , 2020 , 1-2	2.8	1
253	Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2019 , 10, 2040622319865658	4.9	7
252	Chronologic order of appearance of immune-mediated inflammatory diseases relative to diagnosis of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 1283-1291	4.5	7
251	Institute for clinical and economic review (ICER) psoriasis update 2018: what it means for dermatologists treating moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 772-774	2.8	0

250	Real-world drug survival of ixekizumab for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 270-272	4.5	6
249	Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019 , 4, 133-142	1.1	2
248	Safety of long-term interleukin-23 inhibition in patients with psoriasis. <i>British Journal of Dermatology</i> , 2019 , 180, 977-978	4	
247	Burden and Disease Characteristics of Patients with Psoriatic Arthritis: A Population-based Cross-sectional Study. <i>Journal of Rheumatology</i> , 2019 , 46, 716-720	4.1	6
246	Biosimilars for Psoriasis Experience from Europe. <i>Current Dermatology Reports</i> , 2019 , 8, 26-34	1.5	6
245	Review of European registries for psoriasis. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 227-236	2.8	6
244	Treatment of psoriasis with crisaborole. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 156-157	2.8	15
243	Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 318-324	4.6	6
242	How to choose between IL-17 inhibitors and IL-23 inhibitors for psoriasis. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 374-375	2.8	
241	Head-to-head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 42-55	4.6	5
240	Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 110-116	2.8	20
239	Drug survival of secukinumab for psoriasis in a real-world setting. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 150-151	2.8	11
238	Biosimilars in Dermatology: Analytical, Regulatory, and Clinical Considerations: A Treatise From the Medical Board of the National Psoriasis Foundation. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019 , 4, 125-132	1.1	1
237	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 775-804	4.5	47
236	31-Year-Old Female with Psoriasis on Adalimumab with Loss of Effect 2019 , 95-102		
235	46-Year-Old with Psoriasis and Chronic Hepatitis C 2019 , 139-145		
234	Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2019 , 9, 407-420	4	12
233	The Non-compliant Psoriasis Patient 2019 , 71-78		

232 36-Year-Old Severely Obese Male with Worsening Psoriasis **2019**, 79-86

231 A 53-Year-Old Female with Psoriasis and Breast Cancer **2019**, 103-108

230 79-Year-Old Male with Psoriasis and a History of Melanoma In Situ **2019**, 109-115

229 36-Year-Old Female with Bright Red Plaques on the Labia Majora **2019**, 45-51

228 36-Year-Old with Nail Deformities **2019**, 31-37

227 22-Year-Old Male with Pink Plaques on the Face **2019**, 39-44

226 47-Year-Old Given BCG Vaccine as a Child **2019**, 123-129

225 Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *Journal of the American Academy of Dermatology*, **2019**, 80, 1029-1072 4.5 296

224 Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. *Journal of the American Academy of Dermatology*, **2019**, 80, 1073-1113 4.5 145

223 Anti-TNF and Physiologic Measures of Metabolic Disease in Rheumatoid Arthritis. *Journal of Clinical Rheumatology*, **2019**, 25, e54-e56 1.1

222 Risk of first-time and recurrent depression in patients with psoriasis: a population-based cohort study. *British Journal of Dermatology*, **2019**, 180, 116-121 4 20

221 Clinical Goals and Barriers to Effective Psoriasis Care. *Dermatology and Therapy*, **2019**, 9, 5-18 4 44

220 The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment. *Journal of Dermatological Treatment*, **2019**, 30, 446-453 2.8 4

219 YouTube videos on oral systemic therapies for psoriasis: a cross-sectional analysis. *Journal of Dermatological Treatment*, **2019**, 30, 549 2.8 2

218 Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis. *Journal of Medical Economics*, **2019**, 22, 365-371 2.4 10

217 Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. *Journal of Dermatological Treatment*, **2019**, 30, 454-460 2.8 12

216 A cross-sectional study of YouTube videos about psoriasis biologics. *International Journal of Dermatology*, **2019**, 58, e61-e62 1.7 6

215 Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. *Journal of the American Academy of Dermatology*, **2019**, 80, 251-265.e195 186

214	Psoriasis-associated cutaneous pain: etiology, assessment, impact, and management. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 435-440	2.8	12
213	Appearance of lentiginos in psoriasis patient treated with guselkumab. <i>Dermatology Online Journal</i> , 2019 , 25,	1	
212	Apremilast and phototherapy for treatment of psoriasis in a patient with human immunodeficiency virus. <i>Cutis</i> , 2019 , 103, E6-E7	0.4	2
211	Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 671-675	2.8	9
210	Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. <i>British Journal of Dermatology</i> , 2018 , 178, 1064-1071 ⁴		3 ⁰
209	Guselkumab for the treatment of moderate-to-severe plaque psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 333-344	3.8	8
208	The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor- α inhibitors versus phototherapy: An observational cohort study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 60-68	4.5	39
207	Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 769-774	2.8	18
206	Drug survival of secukinumab for moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2018 , 179, 222	4	4
205	Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1320-1326	4.6	22
204	Treatment changes in patients with psoriasis on etanercept or adalimumab: a retrospective chart review. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 664-665	2.8	1
203	The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans. <i>Journal of Medical Economics</i> , 2018 , 21, 537-541	2.4	3
202	Dosage adjustments in patients with psoriasis on adalimumab - a retrospective chart review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, e292-e293	4.6	1
201	Comparison of guidelines for the use of TNF inhibitors for psoriasis in the United States, Canada, Europe and the United Kingdom: a critical appraisal and comprehensive review. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 586-592	2.8	4
200	Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 383-394	4.5	4 ¹
199	Interpreting Clinical Trial Data 2018 , 27-36		2
198	Drug survival of apremilast in patients treated for psoriasis in a real-world setting. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 760-761	4.5	20
197	Atopic dermatitis 2017: where we were 10-15 years ago in psoriasis. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 100-101	2.8	2

196	Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018 , 73, 214-220	9.3	81
195	Review of IL-17 inhibitors for psoriasis. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 347-352	2.8	14
194	Epidemiology of mental health comorbidity in psoriasis. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 487-495	2.8	36
193	Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?. <i>American Journal of Clinical Dermatology</i> , 2018 , 19, 1-13	7.1	39
192	Drug survival of biologic treatments in psoriasis: a systematic review. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 460-466	2.8	50
191	Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 81-89.e5	4.5	95
190	Psoriasis in solid organ transplant patients: best practice recommendations from The Medical Board of the National Psoriasis Foundation. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 329-333	2.8	3
189	Adverse events associated with apremilast use and withdrawal for psoriasis in a real-world setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, e393-e394	4.6	16
188	Localized Scleroderma, Systemic Sclerosis and Cardiovascular Risk: A Danish Nationwide Cohort Study. <i>Acta Dermato-Venereologica</i> , 2018 , 98, 361-365	2.2	9
187	Psoriasiform Hailey-Hailey Disease Presenting as Erythematous Psoriasiform Plaques Throughout the Body: A Case Report 2018 , 22, 17-016		2
186	Building a Citizen Psicentist: Advancing Patient-Centered Psoriasis Research by Empowering Patients as Contributors and Analysts. <i>Dermatology and Therapy</i> , 2018 , 8, 405-423	4	3
185	Reply to: "Comment on 'Drug survival of apremilast for psoriasis in a real-world setting'". <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, e85	4.5	1
184	A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 467-474	2.8	4
183	Review of the mechanism of action of coal tar in psoriasis. <i>Journal of Dermatological Treatment</i> , 2018 , 29, 230-232	2.8	16
182	Risk of aortic aneurysm in patients with psoriasis: a retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, e54-e56	4.6	3
181	Duration of psoriatic arthritis as a risk factor for myocardial infarction. <i>Rheumatology Advances in Practice</i> , 2018 , 2, rky011	1.1	2
180	The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1168-1175	4.6	59
179	Review of U.S. registries for psoriasis. <i>Journal of Dermatological Treatment</i> , 2017 , 28, 697-701	2.8	3

178	Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study. <i>Circulation</i> , 2017 , 136, 263-276	16.7	74
177	Apremilast for a psoriasis patient with HIV and hepatitis C. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, e481-e482	4.6	23
176	A reply to: Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials? <i>British Journal of Dermatology</i> , 2017 , 177, 580-581	4	1
175	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 290-298	4.5	90
174	Sites of recurrence in patients following clearance of psoriasis with biologic therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, e297-e298	4.6	1
173	Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 477-482	4.6	54
172	Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: A Danish nationwide cohort study. <i>Lupus</i> , 2017 , 26, 1435-1439	2.6	19
171	Adalimumab use in patients with psoriasis and hepatitis B: a case series. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, e548-e550	4.6	3
170	Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, e544-e547	4.6	1
169	Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2017 , 376, 2092-2093	59.2	7
168	Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1188-1195	4.6	12
167	Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. <i>JAAD Case Reports</i> , 2017 , 3, 495-497	1.4	15
166	National Psoriasis Foundation Priorities for Patient-Centered Research: Proceedings from the 2016 Conference. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017 , 2, 73-80	1.1	6
165	IL-17 Inhibitors in Moderate-to-Severe Plaque Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017 , 2, 82-82	1.1	
164	Incidence of Pulmonary Arterial Hypertension in Patients with Psoriasis: A Retrospective Cohort Study 2017 , 21, 16-073		8
163	Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017 , 23, 370-381	1.9	13
162	Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. <i>Dermatology and Therapy</i> , 2017 , 7, 365-381	4	30
161	The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 650-656.e3	4.5	48

160	Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1627-1632	4.6	22
159	Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1999-2009	4.6	93
158	How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 569-572	4.5	5
157	Reply to: Comment on "Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review". <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, e169-e170	4.5	
156	Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. <i>British Journal of Dermatology</i> , 2017 , 177, 1495-1502	4	37
155	The risk of melanoma and hematologic cancers in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 639-647.e2	4.5	28
154	Ten-year mortality is increased after hospitalization for atopic dermatitis compared with the general population, but reduced compared with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 98-105	4.5	8
153	Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study. <i>Journal of Dermatological Treatment</i> , 2017 , 28, 290-298	2.8	5
152	Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor- α inhibitors versus methotrexate. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 81-90	4.5	72
151	Biosimilars for psoriasis: clinical studies to determine similarity. <i>British Journal of Dermatology</i> , 2017 , 177, 23-33	4	12
150	41-Year-Old with Nail Deformities 2017 , 21-27		
149	Herpes Zoster Reactivation in a 40-Year-Old with Psoriasis 2017 , 127-132		
148	69-Year-Old with Psoriasis and a History of Skin Cancer 2017 , 117-126		
147	Tuberculosis Infection in a 58-Year-Old with Psoriasis 2017 , 133-141		
146	Infected Joint Prosthesis in a 56-Year-Old with Psoriasis 2017 , 87-94		
145	Persisting Ulcerating Lesions After Cyclosporine Therapy for Erosions Found in Flexural Sites. <i>Skinmed</i> , 2017 , 15, 474-475	0.2	
144	Contemporary management of moderate to severe plaque psoriasis. <i>American Journal of Managed Care</i> , 2017 , 23, S403-S416	2.1	5
143	Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 897-905	4.5	32

142	Psoriasis. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16082	51.1	327
141	Family history predicts major adverse cardiovascular events (MACE) in young adults with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 340-6	4.5	13
140	Non-tuberculous mycobacterial infections in psoriasis patients treated with biologics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, e99-e101	4.6	1
139	Persistence and failure rates of adalimumab monotherapy in biologic-naïve patients with psoriasis: A retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 575-7	4.5	4
138	Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California, 1998-2009 2016 , 20, 4-12		7
137	Ixekizumab 2016 , 153-162		
136	Trends in Type of Original Psoriasis Publications by Decade, 1960 to 2010 2016 , 20, 15-060		2
135	Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting 2016 , 20, 15-151		20
134	Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016 , 22, 396-405	1.9	16
133	Letter regarding Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016 , 1, 61-61	1.1	2
132	Brodalumab, An Anti-IL17RA Monoclonal Antibody, for Psoriasis and Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016 , 1, 91-91	1.1	1
131	Cyclosporine 2016 , 63-73		
130	Biosimilars 2016 , 163-170		0
129	Patient Satisfaction and Quality of Life in Psoriasis and Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016 , 1, 141-141	1.1	
128	Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. <i>British Journal of Dermatology</i> , 2016 , 174, 282-6	4	30
127	Identification of key research needs for topical therapy treatment of psoriasis - a consensus paper by the International Psoriasis Council. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 1115-9	4.6	21
126	From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 798-805.e7	4.5	16
125	Tender Cystic Structure on the Back in an Infant. <i>Skinmed</i> , 2016 , 14, 65-6	0.2	

124	Top-cited psoriasis authors in 4 high-impact dermatology journals: 2000-2012. <i>Dermatology Online Journal</i> , 2016 , 22,	1	
123	Active tuberculosis in a psoriasis patient treated with tumor necrosis factor inhibitors despite an initial negative tuberculin skin test and no known risk factors. <i>Dermatology Online Journal</i> , 2016 , 22,	1	2
122	Oral ponesimod for psoriasis compared to other investigational therapies. <i>Dermatology Online Journal</i> , 2016 , 22,	1	
121	Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 410-9.e6	4.5	49
120	Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. <i>JAMA Dermatology</i> , 2015 , 151, 87-94	5.1	68
119	Association between tumor necrosis factor inhibitor (TNFi) therapy and changes in C-reactive protein (CRP), blood pressure, and alanine aminotransferase (ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, e17-2	4.5	6
118	Antiviral gene expression in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 1951-7	4.6	24
117	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015 , 373, 1318-28	59.2	530
116	Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 329-31	4.5	7
115	Preventing hepatitis B reactivation associated with immunosuppressive drug treatments for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 881-2	4.5	6
114	Survey of trends and gaps in dermatologists' cardiovascular screening practices in psoriasis patients: Areas still in need of improvement. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 872-4.e4	4.5	9
113	Comment on "Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors". <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, e121	4.5	1
112	Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 955-63	4.6	63
111	Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 78-84	4.5	19
110	Photodynamic therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2015 , 26, 202-7	2.8	31
109	The Evolving Role of Primary Care Practitioners in Dermatology. <i>Journal of the Dermatology Nurses Association</i> , 2015 , 7, 325-329	0.2	1
108	Total cholesterol, lipoprotein, and triglyceride levels in tumor necrosis factor inhibitor-treated patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis. <i>International Journal of Dermatology</i> , 2015 , 54, e442-5	1.7	3
107	An updated survey for the 2007-2013 period of randomized controlled trials for psoriasis: treatment modalities, study designs, comparators, outcome measures and sponsorship. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 1945-50	4.6	4

106	Trends in the frequency of original research in acne vulgaris, rosacea, dermatitis, psoriasis, skin cancer, and skin infections, 1970-2010 2015 , 19, 44-7		4
105	Pemphigus vulgaris with tense bullae 2015 , 19, 77-8		0
104	Risk of myocardial infarction in psoriasis patients: a retrospective cohort study. <i>Journal of Dermatological Treatment</i> , 2015 , 26, 230-4	2.8	27
103	No association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis patients. <i>Journal of Drugs in Dermatology</i> , 2015 , 14, 159-66	2.2	14
102	Factors affecting academic leadership in dermatology. <i>Cutis</i> , 2015 , 95, 98-102	0.4	
101	Factors affecting the pursuit of academic careers among dermatology residents. <i>Cutis</i> , 2015 , 95, 231-6	0.4	4
100	Time to Raise the Bar to Psoriasis Area Severity Index 90 and 100. <i>Journal of Drugs in Dermatology</i> , 2015 , 14, 1086-8	2.2	21
99	Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors. <i>American Journal of Clinical Dermatology</i> , 2014 , 15, 45-50	7.1	24
98	An update on drug-drug interactions with biologics for the treatment of moderate-to-severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2014 , 25, 87-9	2.8	12
97	The risk of deep fungal infections during biologic therapy for psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 1277-85	4.6	3
96	Bariatric surgery and psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 774-779	4.5	15
95	The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 846-52	4.6	47
94	Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 1380-7	4.6	6
93	Relationship between tumor necrosis factor- α inhibitors and cardiovascular disease in psoriasis: a review 2014 , 18, 49-54		14
92	Most common dermatologic topics published in five high-impact general medical journals, 1970-2012: melanoma, psoriasis, herpes simplex, herpes zoster, and acne 2014 , 18, 29-31		2
91	US dermatology residency program rankings. <i>Cutis</i> , 2014 , 94, 189-94	0.4	6
90	A randomized, head-to-head pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 899-906	4.6	26
89	Association of ethnicity, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, 167-8	4.5	8

88	Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 842-9	2.6	72
87	Bullous drug eruption in a patient with psoriasis after a test dose of methotrexate. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, e264-e265	4.5	2
86	Association of gender, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, 650-1	4.5	12
85	Tumor Necrosis Factor-Triad: Psoriasis, Cardiovascular Disease, and Depression. <i>Psoriasis Forum</i> , 2013 , 19a, 41-49		2
84	Images in clinical medicine. Psoriasis flare from Koebner's phenomenon after acupuncture. <i>New England Journal of Medicine</i> , 2013 , 368, 1635	59.2	3
83	Tumor necrosis factor inhibitors and myocardial infarction in psoriasis. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 310, 1075-6	27.4	3
82	Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009. <i>Journal of Rheumatology</i> , 2013 , 40, 1218-25	4.1	56
81	Axillary granular parakeratosis. <i>Cutis</i> , 2013 , 92, 61, 65-6	0.4	
80	Partial reversal of androgenetic alopecia with methotrexate therapy for psoriasis. <i>Cutis</i> , 2013 , 92, 127-8	0.4	1
79	Combination therapy with tumor necrosis factor inhibitors in psoriasis treatment. <i>Cutis</i> , 2013 , 92, 140-7	0.4	7
78	The association of psoriasis with autoimmune diseases. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 924-30	4.5	128
77	A Review of the Epidemiology of Cardiovascular Comorbidities in Psoriasis. <i>Current Dermatology Reports</i> , 2012 , 1, 14-22	1.5	
76	Association of systemic psoriasis therapies and incidence of myocardial infarction. <i>British Journal of Dermatology</i> , 2012 , 166, 232; author reply 233	4	4
75	Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. <i>Archives of Dermatology</i> , 2012 , 148, 1244-50		214
74	Cutaneous manifestations of category A bioweapons. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 1213.e1-1213.e15	4.5	14
73	Low prevalence of psoriasis among children and adolescents in a large multiethnic cohort in southern California. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 957-64	4.5	34
72	Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 870	4.5	63
71	Wnt signaling regulates hepatic metabolism. <i>Science Signaling</i> , 2011 , 4, ra6	8.8	129

70	A Clinical Study Comparing the Efficacy of Halobetasol Propionate 0.05% Ointment Once Daily versus Twice Daily in Combination with Ammonium Lactate Lotion in the Treatment of Stable Plaque Psoriasis. <i>Psoriasis Forum</i> , 2011 , 17a, 2-8		1
69	The association of psoriasis and elevated blood lipids in overweight and obese children. <i>Journal of Pediatrics</i> , 2011 , 159, 577-83	3.6	81
68	Medical students educate teens about skin cancer: what have we learned?. <i>Journal of Cancer Education</i> , 2011 , 26, 153-5	1.8	7
67	Interaction between adalimumab with concurrent pregabalin and duloxetine administration in a psoriasis patient with diabetic peripheral neuropathy. <i>Cutis</i> , 2011 , 87, 249-50	0.4	5
66	Sunitinib-induced hand-foot syndrome: a new, distinct form. <i>Clinical and Experimental Dermatology</i> , 2010 , 35, 200-1	1.8	5
65	Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection. <i>Clinical and Experimental Dermatology</i> , 2010 , 35, 397-8	1.8	23
64	Localized contact urticaria caused by lidocaine/tetracaine peel. <i>Archives of Dermatology</i> , 2009 , 145, 499-500		6
63	Erythematous papules and pustules on the scalp. <i>Pediatric Dermatology</i> , 2009 , 26, 195-6	1.9	
62	Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. <i>Dermatologic Therapy</i> , 2009 , 22, 61-73	2.2	72
61	Generalized chrysiasis improved with pulsed dye laser. <i>Dermatologic Surgery</i> , 2009 , 35, 538-42	1.7	11
60	308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009 , 23, 36-41	4.6	31
59	Bortezomib-induced histiocytoid Sweet syndrome. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 496-7	4.5	41
58	Habit tic deformity secondary to guitar playing. <i>Dermatology Online Journal</i> , 2009 , 15, 16	1	2
57	Graduates-of-foreign-dermatology residencies and military dermatology residencies and women in academic dermatology. <i>Dermatology Online Journal</i> , 2009 , 15, 2	1	
56	Kaiser Permanente: a new model for academic dermatology. <i>Dermatology Online Journal</i> , 2009 , 15, 13	1	
55	Calcinosis cutis of juvenile dermatomyositis treated with incision and drainage. <i>Dermatologic Surgery</i> , 2008 , 34, 575-7	1.7	22
54	Letter: clear margins after the use of imatinib mesylate prior to resection of extensive dermatofibrosarcoma protuberans. <i>Dermatologic Surgery</i> , 2008 , 34, 1151	1.7	1
53	Cutaneous horn on the finger. <i>Clinical and Experimental Dermatology</i> , 2008 , 33, 529-30	1.8	1

52	An indurated, enlarged lower lip. <i>Clinical and Experimental Dermatology</i> , 2008 , 33, 799-800	1.8	2
51	Erythematous, eczematous papules appearing in the spring. <i>Clinical and Experimental Dermatology</i> , 2008 , 33, 217-8	1.8	1
50	Interleukin-12, interleukin-23, and psoriasis: ABT-874 in clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 1083; author reply 1083	4.5	3
49	The Nikolskiy sign. <i>Archives of Dermatology</i> , 2008 , 144, 1140		1
48	MD/PhDs are more likely than MDs to choose a career in academic dermatology. <i>Dermatology Online Journal</i> , 2008 , 14, 27	1	
47	Confluent and reticulate papillomatosis. <i>Dermatology Online Journal</i> , 2008 , 14, 10	1	
46	Chronically painful right thumb with pustules and onycholysis. Diagnosis: acrodermatitis continua of Hallopeau. <i>Clinical and Experimental Dermatology</i> , 2007 , 32, 619-20	1.8	14
45	Topical kinetin 0.1% lotion for improving the signs and symptoms of rosacea. <i>Clinical and Experimental Dermatology</i> , 2007 , 32, 693-5	1.8	27
44	Histopathologic findings of disseminated coccidioidomycosis with hyphae. <i>Archives of Dermatology</i> , 2007 , 143, 548-9		2
43	Clinical improvement of pityriasis rubra pilaris with combination etanercept and acitretin therapy. <i>Archives of Dermatology</i> , 2007 , 143, 1597-9		27
42	Patients seen and lessons learned. <i>Clinics in Dermatology</i> , 2007 , 25, 144-5; discussion 145	3	2
41	Current strategies to address the ongoing shortage of academic dermatologists. <i>Journal of the American Academy of Dermatology</i> , 2007 , 56, 1065-6	4.5	2
40	Ranking the dermatology programs based on measurements of academic achievement. <i>Dermatology Online Journal</i> , 2007 , 13, 3	1	37
39	A unique pattern of hyperhidrosis and herpes zoster. <i>Archives of Dermatology</i> , 2006 , 142, 1069		5
38	Morgellons disease: a rapport-enhancing term for delusions of parasitosis. <i>Journal of the American Academy of Dermatology</i> , 2006 , 55, 913-4	4.5	34
37	Estrogen and the skin. <i>Journal of the American Academy of Dermatology</i> , 2006 , 55, 1115-6	4.5	
36	Rickettsial infections 2006 , 279-296		1
35	Postherpetic poliosis. <i>Archives of Dermatology</i> , 2006 , 142, 250-1		10

34	Dermatology residency program characteristics that correlate with graduates selecting an academic dermatology career. <i>Archives of Dermatology</i> , 2006 , 142, 845-50		22
33	Dermographism secondary to trauma from a coral reef. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006 , 20, 1337-8	4.6	3
32	West Nile virus rash on the palms and soles of the feet. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006 , 20, 1393-4	4.6	2
31	Thalidomide, semen distribution, teratogenicity and cost: reply from authors. <i>British Journal of Dermatology</i> , 2006 , 154, 563-564	4	
30	Cutaneous metastasis to the chest wall from prostate cancer. <i>International Journal of Dermatology</i> , 2006 , 45, 946-8	1.7	18
29	An unusual presentation of two simultaneous primary melanomas. <i>International Journal of Dermatology</i> , 2006 , 45, 580-2	1.7	3
28	Tropical manifestations of common viral infections 2006 , 171-183		
27	Issues for travelers 2006 , 13-19		
26	Advances in antiviral therapy. <i>Dermatologic Clinics</i> , 2005 , 23, 313-22	4.2	11
25	Rickettsial Infections around the World, Part 2: Rickettsialpox, the Typhus Group, and Bioterrorism. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005 , 9, 105-115	1.6	1
24	Thalidomide: dermatological indications, mechanisms of action and side-effects. <i>British Journal of Dermatology</i> , 2005 , 153, 254-73	4	155
23	Rickettsial infections around the world, part 1: pathophysiology and the spotted fever group. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005 , 9, 54-62	1.6	3
22	Rickettsial infections around the world, part 2: rickettsialpox, the typhus group, and bioterrorism. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005 , 9, 105-15	1.6	4
21	Rickettsial Infections around the World, Part 1: Pathophysiology and the Spotted Fever Group. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005 , 9, 54-62	1.6	3
20	Emerging therapies for herpes viral infections (types 1 - 8). <i>Expert Opinion on Emerging Drugs</i> , 2004 , 9, 237-56	3.7	7
19	Therapy of common superficial fungal infections. <i>Dermatologic Therapy</i> , 2004 , 17, 517-22	2.2	17
18	Subcutaneous fungal infections. <i>Dermatologic Therapy</i> , 2004 , 17, 523-31	2.2	77
17	Therapy of systemic fungal infections. <i>Dermatologic Therapy</i> , 2004 , 17, 532-8	2.2	9

16	Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. <i>Antiviral Research</i> , 2004 , 64, 79-83	10.8	45
15	A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. <i>Journal of Infection</i> , 2004 , 49, 179-209	18.9	39
14	Reactive hemophagocytosis associated with the initiation of highly active antiretroviral therapy (HAART) in a patient with AIDS. <i>Scandinavian Journal of Infectious Diseases</i> , 2004 , 36, 516-9		24
13	Selected sexually transmitted diseases and their relationship to HIV. <i>Clinics in Dermatology</i> , 2004 , 22, 499-508	3	19
12	Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, 495-528; quiz 529-32	4.5	17
11	Toxic epidermal necrolysis as a complication of treatment with voriconazole. <i>Southern Medical Journal</i> , 2004 , 97, 1116-7	0.6	10
10	Valacyclovir in the Treatment of Herpes Simplex, Herpes Zoster, and other Viral Infections. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003 , 7, 372-381	1.6	6
9	Valacyclovir in the treatment of herpes simplex, herpes zoster, and other viral infections. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003 , 7, 372-81	1.6	6
8	Secondary cutaneous anaplastic large cell lymphoma treated with liposomal doxorubicin (Doxil) leading to complete remission. <i>International Journal of Dermatology</i> , 2003 , 42, 464-5	1.7	2
7	Verruciform xanthoma in association with milroy disease and leaky capillary syndrome. <i>Pediatric Dermatology</i> , 2003 , 20, 44-7	1.9	29
6	Bullous phytophotodermatitis associated with high natural concentrations of furanocoumarins in limes. <i>American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society</i> , 2002 , 13, 10-4		41
5	A case of air bag dermatitis. <i>Archives of Dermatology</i> , 2002 , 138, 1383-4		6
4	A case of elastosis perforans serpiginosa. <i>Cutis</i> , 2002 , 69, 423-5	0.4	5
3	Squamous cell carcinoma in solid-organ transplantation. <i>Dermatology Online Journal</i> , 2002 , 8, 4	1	64
2	Cytokine-induced metabolic dysfunction of MIN6 beta cells is nitric oxide independent. <i>Journal of Surgical Research</i> , 2001 , 101, 190-5	2.5	14
1	Effects of simulated source of tremor on acoustic and airflow voice measures. <i>Journal of Voice</i> , 2000 , 14, 47-57	1.9	7